SCHEMBL184791

SCHEMBL184791

O=C(O)NCc1cccc(CNCc2ccc(C(F)(F)F)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.51
MTOR P42345 2/20 0.51
MAPK14 Q16539 2/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2D6 P10635 2/20 0.50
CYP2C19 P33261 2/20 0.50
CYP2C9 P11712 1/20 0.50
TSHR P16473 1/20 0.50
CYP19A1 P11511 1/20 0.49
MC4R P32245 1/20 0.48
ALDH1A1 P00352 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MEN1 O00255 2/20 0.48
GAA P10253 2/20 0.48
KMT2A Q03164 2/20 0.48
MAPT P10636 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
LMNA P02545 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1695141 0.86 MTOR (0.58) MTORMAPK14CYP1A2CYP2D6CYP2C19
SCHEMBL185065 0.85 CYP1A2 (0.68) CYP1A2CYP2D6CYP2C19CYP2C9TSHR
SCHEMBL30661718 0.83 MLYCD (0.65) MLYCDMAPK14CYP1A2CYP2D6CYP2C19
SCHEMBL1855508 0.83 MRGPRX4 (0.61) MLYCDSMN1; SMN2
SCHEMBL185129 0.82 GLS (0.47) MLYCDMTORMAPK14L3MBTL1
Hydrochloric Acid SCHEMBL1852091 0.82 MRGPRX4 (0.60) SMN1; SMN2
SCHEMBL195675 0.81 CYP1A2 (0.58) CYP1A2CYP2D6CYP2C19CYP2C9TSHR
SCHEMBL15157842 0.80 SRC (0.54) CYP1A2CYP2D6CYP2C19CYP2C9TSHR
SCHEMBL5227682 0.80 DPP7 (0.57) MLYCDCYP1A2CYP2D6CYP2C19CYP19A1
SCHEMBL28387015 0.79 MEN1 (0.54) MAPK14TSHRALDH1A1MEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501992-B2 Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-06 US disclosed
EP-2297103-B1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-01-04 EP disclosed
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-12-01 US disclosed
EP-2297103-A1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS Bristol-Myers Squibb Company (US) 2011-03-23 EP disclosed
WO-2009152082-A1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BCL2, BAX, BCL2A1 MLYCD 2965/4885MTOR 628/4885MAPK14 1213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.